Dio-sensimedia: A novel culture medium for rapid detection of extended spectrum β-lactamases

BMC Infectious Diseases

Volumn 3, Issue , 2003, Pages

  Cagatay, Atahan A ^a   Kocagoz, Tanil ^b   Eraksoy, Haluk ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b The Acibadem Healthcare Group   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPIRATION; BACTERIUM CULTURE; BACTERIUM ISOLATE; BLOOD CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; ENTEROBACTERIACEAE; ENZYME ASSAY; ENZYME SYNTHESIS; ESCHERICHIA COLI; HEALTH CARE COST; INTERMETHOD COMPARISON; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MORTALITY; NONHUMAN; PLASMID; PUS; STAPHYLOCOCCUS; URINE CULTURE;

AGAR; BACTERIAL TYPING TECHNIQUES; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CULTURE MEDIA; ESCHERICHIA COLI; HUMANS; KLEBSIELLA PNEUMONIAE; SENSITIVITY AND SPECIFICITY;

EID: 2442694174     PISSN: 14712334     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2334-3-22     Document Type: Article

References (27)

1. Shah PW and Stille W: Escherichia coli and Klebsiella pneumoniae strains more susceptible to cefoxitin than to third generation cephalosporins [Letter]. J Antimicrob Chemother 1983, 11:597-8.
2. Jarlier V, Nicolas MH, Fournier G and Philippon A: Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae : Hospital prevalence and susceptibility pattern. Rev Infect Dis 1988, 10:867-78.
3. Jacoby GA, Medeiros AA, O'Brien TF, Pinto ME and Jiang H: Broad-spectrum, transmissible beta-lactamases. N Engl J Med 1988, 319:723-4.
4. Quinn JP, Miyashiro D, Sahm D, Flamm R and Bush K: Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1989, 33:1451-6.
5. Diekema DJ, Pfaller MA, Jones RN and and the SENTRY participants Group (Americas) et al.: Survey of bloodstream infections due to gram-negative bacilli: Frequency of occurence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program 1997. Clin Infect Dis 1999, 29:595-607.
6. Philippon A, Arlet G and Lagrance PH: Origin and impact of plasmid-mediated extended spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 1994, 13:17-29.
7. Philippon A, Labia R and Jacoby G: Extended-spectrum β-lactamases. Antimicrob Agents Chemother 1989, 33:1131-6.
8. Nordman P and Guibert M: Extended-spectrum β-lactamases in Pseudomonas aeruginosa. J Antimicrob Chemother 1998, 42:128-31.
9. Bush K, Jacoby GA. and Medeiros AA: A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995, 39:1211-33.
10. Jacoby GA and Medeiros AA: More extended spectrum β-lactamases. Antimicrob Agents Chemother 1991, 35:1697-1704.
11. Livermore DM and Brown DF: Detection of β-lactamase-mediated resistance. J Antimicrob Chemother 2001, 48(Suppl Sl):59-64.
12. Patterson JE: Extended-spectrum β-lactamase-producing Gram-negative bacilli. Seminars in Infect Control 2001, 1(3):184-90.
13. Nathisuwan S, Burgess DS and Lewis JS II: Extended-spectrum β-lactamases: Epidemiology, detection, and treatment. Pharmacotherapy 2001, 21(8):920-8.
14. Mugnier P, Casin I, Bouthors AT and Collatz E: Novel OXA-10-derived extended-spectrum betalactamases selected in vivo or in vitro. Antimicrob Agents Chemother 1998, 42:3113-6.
15. Paterson DL, Mulazimoglu L and Casellas JM et al.: Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000, 30:473-8.
16. Poutsiaka DD: Antimicrobial resistance in the chronically critically ill patient. Clin Chest Med 2001, 22:87-103.
17. Katsanis GP, Spargo J, Ferraro MJ, Sutton L and Jacoby GA: Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases. J Clin Microbiol 1994, 32:691-6.
18. Sanders CC, Barry AL and Washington JA et al.: Detection of extended-spectrum betalactamase-producing members of the family Enterobacteriaceae with the VITEK ESBL test. J Clin Microbiol 1996, 34:2997-3001.
19. Livermore DM, Struelens M and Amorim J et al.: Multicentre evaluation of the Vitek 2 advanced expert system for interpretive reading of antimicrobial resistance tests. J Antimicrobiol Chemother 2002, 49:289-300.
20. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing; Eleventh Informational Supplement. NCCLS document M100-S11. Wayne Pa: NCCLS 2001.
21. Jacoby JA and Sutton L: Properties of plasmids responsible for production of extended spectrum β-lactamases. Antimicrob Agents Chemother 1991, 35:164-9.
22. Levy SB, Fitzgerald GB and Macone AB: Changes in intestinal flora of farm personnel after introduction of a tetracycline-supplemented feed on a farm. N Engl J Med 1976, 295:583-8.
23. Barenfanger J, Drake C and Kacich G: Clinical and financial benefits of rapid bacterial identification and antimicrobial susceptibility testing. J Clin Microbiol 1999, 37:1415-8.
24. Doern G, Vautour R, Gaudet M and Levy B: Clinical impact of rapid in vitro susceptibility testing and bacterial identification. J Clin Microbiol 1994, 32:1757-62.
25. McGregor A, Schio F, Beaton S, Boulton V, Perman M and Gilbert G: The MicroScan WalkAway diagnostic microbiology system evaluation. Pathology 1995, 27:172-6.
26. Ling TK, Tam PC, Liu ZK and Cheng AFB: Evaluation of VITEK 2 rapid identification and susceptibility testing system against Gram-negative clinical isolates. J Clin Microbiol 2001, 39(8):2964-6.
27. Cormican MG, Marshall SA and Jones RN: Detection of extended-spectrum β-lactamase (ESBL)-producing strains by the E-test ESBL screen. J Clin Microbiol 1996, 34(8):1880-4.